Open access
Open access
Powered by Google Translator Translator

Critical Care

COVID-19 updated evidence: a Cochrane round-up.

18 Jan, 2022 | 09:53h | UTC

COVID-19 evidence: a Cochrane round-up – Cochrane Library

 

Pro-Con Debate: Cardiac Troponin measurement as part of routine follow-up of myocardial damage following noncardiac surgery.

18 Jan, 2022 | 09:36h | UTC

Pro-Con Debate: Cardiac Troponin Measurement as Part of Routine Follow-up of Myocardial Damage Following Noncardiac Surgery – Anesthesia & Analgesia

 

Cluster-randomized trial: Antiseptic bathing with 2% chlorhexidine-impregnated cloths and 0.08% octenidine wash mitts were not effective for preventing central-line associated bloodstream infections in intensive care patients.

18 Jan, 2022 | 09:18h | UTC

Effect of antiseptic bathing with chlorhexidine or octenidine on central-line associated bloodstream infections in intensive care patients: a cluster-randomised controlled trial – Clinical Microbiology and Infection

 

WHO recommends two new drugs (Baricitinib and Sotrovimab) to treat COVID-19.

17 Jan, 2022 | 00:48h | UTC

News release: WHO recommends two new drugs to treat COVID-19 – World Health Organization

Infographic with the updated recommendations: A living WHO guideline on drugs for covid-19 – The BMJ

Commentaries:

WHO Recommends Two New COVID-19 Treatments – Cost and Availability Likely Barriers – Health Policy Watch

Expert reaction to WHO recommending two drugs, sotrovimab and baricitinib, to treat patients with COVID-19 – Science Media Centre

 

Commentary on Twitter (thread – click for more)

 

Guidelines for the provision of nutrition support therapy in the adult critically ill patient.

16 Jan, 2022 | 23:19h | UTC

Guidelines for the provision of nutrition support therapy in the adult critically ill patient: The American Society for Parenteral and Enteral Nutrition – Journal of Parenteral and Enteral Nutrition

 

RCT: In patients undergoing emergency endotracheal intubation, 7-day survival was significantly lower with etomidate vs. ketamine (77.3% versus 85.1%), but 28 survival rates were not significantly different (etomidate 64.1% vs. ketamine 66.8%, p = 0.294).

16 Jan, 2022 | 23:09h | UTC

Etomidate versus ketamine for emergency endotracheal intubation: a randomized clinical trial – Intensive Care Medicine

Commentary: SGEM#356: Drugs are gonna knock you out – etomidate vs. ketamine for emergency endotracheal intubation – The Skeptics’ Guide to EM

 

Commentary on Twitter

 

Editorial: Towards evidence-based staffing: the promise and pitfalls of patient-to-intensivist ratios.

16 Jan, 2022 | 22:45h | UTC

Towards evidence-based staffing: the promise and pitfalls of patient-to-intensivist ratios – Intensive Care Medicine (free for a limited period)

Related Study: Association of patient-to-intensivist ratio with hospital mortality in Australia and New Zealand – Intensive Care Medicine

 

Commentary on Twitter

 

Systematic Review: Restrictive transfusion thresholds can safely decrease transfusions by 41% across a broad range of clinical contexts.

14 Jan, 2022 | 08:18h | UTC

Transfusion thresholds for guiding red blood cell transfusion – Cochrane Library

Summary: Is it safe to use lower blood counts (haemoglobin levels) as a trigger for blood transfusion in order to give fewer blood transfusions? – Cochrane Library

Related:

RCT: Among patients with acute MI and anemia, a restrictive transfusion strategy resulted in a noninferior rate of major cardiovascular events compared to a liberal transfusion strategy

Randomized trial: Liberal vs. restrictive transfusion thresholds in extremely low-birth-weight infants

Meta-Analysis: Effects of Restrictive vs. Liberal Transfusion Strategies on Longer-term Outcomes After Cardiac Surgery

Randomized Trial: In Patients Undergoing Cardiac Surgery, A Restrictive Transfusion Approach Does Not Increase the Risk of Acute Kidney Injury

Effects of restrictive red blood cell transfusion on the prognoses of adult patients undergoing cardiac surgery: a meta-analysis of randomized controlled trials – Critical Care

Research: Restrictive or Liberal Red-Cell Transfusion for Cardiac Surgery

Transfusion Requirements After Cardiac Surgery: The TRACS Randomized Controlled Trial – JAMA

 

Commentary on Twitter

https://twitter.com/cochraneINJ/status/1473667822542888964

 

Another study showed neutralizing monoclonal antibody therapies are not effective when given after the patient is already hospitalized.

13 Jan, 2022 | 08:48h | UTC

Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial – The Lancet Infectious Diseases

Invited Commentary: Time to knock monoclonal antibodies off the platform for patients hospitalised with COVID-19

 

The COVID-19 Treatment Guidelines Panel’s Statement on Anticoagulation in Hospitalized Patients With COVID-19 – in the absence of contraindications, use therapeutic-dose anticoagulation with low molecular weight heparin for hospitalized patients not in the ICU who have a D-dimer above the upper limit of normal.

12 Jan, 2022 | 09:11h | UTC

The COVID-19 Treatment Guidelines Panel’s Statement on Anticoagulation in Hospitalized Patients With COVID-19 – NIH COVID-19 Treatment Guidelines

 

German Guideline: Oxygen therapy in the acute care of adult patients.

12 Jan, 2022 | 08:57h | UTC

German S3 Guideline: Oxygen Therapy in the Acute Care of Adult Patients – Respiration

 

Review: Management of coagulopathy in bleeding patients.

12 Jan, 2022 | 08:34h | UTC

Management of Coagulopathy in Bleeding Patients – Journal of Clinical Medicine

 

Clinical Guideline: Acute-on-chronic liver failure.

11 Jan, 2022 | 02:43h | UTC

Acute-on-Chronic Liver Failure Clinical Guidelines – American Journal of Gastroenterology

Related: Guidelines for the Management of Adult Acute and Acute-on-Chronic Liver Failure in the ICU

 

Commentary on Twitter

 

Special Issue: Peri‐operative and critical care management of the brain ‐ current evidence.

11 Jan, 2022 | 02:36h | UTC

Homepage: Special Issue:Peri‐operative and critical care management of the brain ‐ current evidence – Anaesthesia

Editorials:

In search of the perfect outcome in neuroanaesthesia and neurocritical care

Anaesthesia and the older brain: what should we do?

Review Articles:

Implications of nocebo in anaesthesia care

Chronic subdural haematoma: the role of peri-operative medicine in a common form of reversible brain injury

Acute peri-operative neurocognitive disorders: a narrative review

Pragmatic sedation strategies to prevent secondary brain injury in low-resource settings

Delirium and COVID-19: a narrative review of emerging evidence

Anaesthesia for mechanical thrombectomy: a narrative review

Clinical applications of point-of-care ultrasound in brain injury: a narrative review

Management of status epilepticus: a narrative review

Evidence-based strategies to reduce the incidence of postoperative delirium: a narrative review

Management of traumatic brain injury: a narrative review of current evidence

Peri-operative neurological monitoring with electroencephalography and cerebral oximetry: a narrative review

Peri-operative management of patients with Parkinson’s disease

 

Clinical Practice Guideline Summary: Recommended Drugs and Biologics in Adult Patients with COVID-19.

11 Jan, 2022 | 01:26h | UTC

Clinical Practice Guideline Summary: Recommended Drugs and Biologics in Adult Patients with COVID-19 – Covid Advisory for Ontario

 

Commentary on Twitter

 

RCT: Among patients hospitalized with COVID-19 at increased risk for venous thromboembolism, post-discharge thromboprophylaxis with Rivaroxaban for 35 days may improve outcomes.

17 Dec, 2021 | 09:50h | UTC

Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial – The Lancet

Invited commentary: Anticoagulation in COVID-19 – The Lancet

 

Commentary on Twitter

 

NICE Guideline | Acute heart failure: diagnosis and management.

17 Dec, 2021 | 08:48h | UTC

Acute heart failure: diagnosis and management – National Institute for Health and Care Excellence

Related: #ESCCongress – 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure – SGLT2 inhibitors are now recommended for patients with heart failure with reduced ejection fraction regardless of the presence of diabetes.

 

Year In Review: Top Non-COVID Infectious Diseases Articles Of 2021.

17 Dec, 2021 | 08:36h | UTC

Year In Review: Top Non-COVID Infectious Diseases Articles Of 2021 – IDStewardship

 

Commentary on Twitter

 

Merck’s COVID pill loses its luster: what that means for the pandemic – “Molnupiravir was initially heralded by public-health officials as a game-changer for COVID-19, but full clinical-trial data showed lower-than-expected efficacy”.

16 Dec, 2021 | 09:52h | UTC

Merck’s COVID pill loses its lustre: what that means for the pandemic – Nature

Related:

FDA panel narrowly recommends authorization of first antiviral pill to treat COVID.

[Press release – not published yet] Merck’s new Covid-19 pill Molnupiravir updated data shows reduced efficacy (30%) for preventing hospitalization and death compared to initial results (50%). Absolute risk reduction of hospitalization and death fell from 7% to 3%.

8 lingering questions about the new Covid pills from Merck and Pfizer.

COVID antiviral pills: what scientists still want to know – “Drugs like Molnupiravir and Paxlovid could change the course of the pandemic if clinical trial results hold up in the real world”.

[Press release – not published yet] RCT: Pfizer’s novel Covid-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of phase 2/3 EPIC-HR study.

A prominent virologist warns new COVID-19 pill could unleash dangerous mutants. Others see little cause for alarm.

The U.K. approves Merck’s COVID-19 antiviral pill, calling it a world first.

Merck to allow other nations to produce new COVID-19 antiviral.

Video: Merck’s Covid pill could transform treatment. Here’s how it works.

How antiviral pill Molnupiravir shot ahead in the COVID drug hunt.

What we know — and don’t know — about Merck’s new Covid-19 pill.

[Press release – not published yet] Merck announces oral antiviral Molnupiravir reduced the risk of hospitalization or death by approximately 50 Percent compared to placebo for patients with mild or moderate COVID-19.

Merck’s Covid-19 pill is great news but may not be a game-changer.

Video | A Pill For COVID? A Doctor Explains Molnupiravir.

 

Recommendations for antibiotic selection for severe nosocomial infections.

16 Dec, 2021 | 09:40h | UTC

Recommendations for antibiotic selection for severe nosocomial infections – Revista Espanola de Quimioterapia

 

Review: Impact of obesity in critical illness.

16 Dec, 2021 | 08:45h | UTC

Impact of Obesity in Critical Illness – CHEST

 

A guide to enteral nutrition in intensive care units: 10 expert tips for the daily practice.

16 Dec, 2021 | 08:47h | UTC

A guide to enteral nutrition in intensive care units: 10 expert tips for the daily practice – Critical Care

 

Infectious diseases learning pearls from inpatient ID consults.

15 Dec, 2021 | 08:22h | UTC

ID Learning Units from Inpatient ID Consults – HIV and ID Observations

 

Podcast: No tension about inpatient hypertension.

14 Dec, 2021 | 08:39h | UTC

#310 No Tension About Inpatient Hypertension with Dr. Noble Maleque – The Curbsiders

 

How to recognize and manage COVID-19-associated coagulopathy.

13 Dec, 2021 | 09:45h | UTC

How to recognize and manage COVID-19-associated coagulopathy – Hematology, ASH Education Program

 

Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.